JNJ250103C136000
- 0.00
- 0.000.00%
Johnson & Johnson Newsroom
Market Sells CES Tech News, ISM Tuesday as Nvidia Champions Robots Monday | Live Stock
Johnson & Johnson Drug Combination Shows Positive Results in Lung Cancer Study
Johnson & Johnson Announces RYBREVANT Plus LAZCLUZE Show Statistically Significant And Clinically Meaningful Improvement In Overall Survival Versus Osimertinib; Median Overall Survival Improvement Expected To Exceed One Year; First And Only Regimen...
Express News | J&J: Rybrevant Plus Lazcluze Shows Statistically Significant & Clinically Meaningful Improvement in Overall Survival Vs Osimertinib
Express News | J&J: Median Overall Survival Improvement With Rybrevant Plus Lazcluze Expected to Exceed One Year
Market Climbed Monday Just Past Santa Rally High Water Mark | Wall Street Today
Stock Of The Day: Will Johnson & Johnson Take The Market Lower?
CES Tech Conference Week Starts with Nvidia and Chips Climbing | Live Stock
SA Asks: Which Biotechs Are Most Likely to Be Acquired Near-term?
Santa Clause Came and Went Without Bringing Gifts | Weekly Buzz
Friday? More Like Grinch Day | Wall Street Today
Best Income Ideas for 2025: Stocks, Bonds, and Everything in Between
Santa Claus Came Without Rallying the Troops | Live Stock
Dividend Roundup: Johnson & Johnson, JPMorgan, Oracle, Mastercard, and More
Johnson & Johnson To Go Ex-Dividend On February 18th, 2025 With 1.24 USD Dividend Per Share
U.S. Companies With Potential Pension Risk Transfer Restructuring Opportunities
5 Low-Leverage Stocks Worth Adding to Your Portfolio in 2025
Smart Money Is Betting Big In JNJ Options
Johnson & Johnson Declares $1.24 Quarterly Dividend; 3.4% Yield
Press Release: Johnson & Johnson Announces Quarterly Dividend for First Quarter 2025